查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594668

鴉片類藥物引起的便秘市場：按活性成分、藥物類別、給藥方式、分銷管道分類 - 2025-2030 年全球預測

Opioid Induced Constipation Market by Active Ingredients, Drug Class, Mode of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年鴉片類藥物引起的便秘市場價值為6595萬美元，預計到2024年將達到7010萬美元，複合年成長率為6.69%，預計到2030年將達到1.0378億美元。

鴉片類藥物引起的便秘（OIC）是使用鴉片類鎮痛藥進行疼痛管理的患者常見的副作用，已成為製藥公司和醫療保健提供者關注的重要領域。慢性疼痛的增加和鴉片類藥物消費量的增加增加了對有效的 OIC 管理解決方案的需求。主要用途包括處方藥、非處方藥和旨在緩解便秘症狀的非藥物干預措施。最終用戶範圍從醫院到居家照護機構再到專科診所。關鍵的成長要素包括對鴉片類藥物副作用的認知提高、藥物配方的進步以及醫療保健支出的增加。最新的機會在於個人化醫療方法，該方法側重於針對患者的特定解決方案，並考慮影響便秘的遺傳和生活方式因素。公司可以透過投資患者教育和開發全面的 OIC 管理計劃來利用這些機會。然而，它面臨著挑戰​​，包括新藥認證的嚴格監管要求、長期使用鴉片類藥物帶來的恥辱，以及準確診斷 OIC 和其他類型便秘的複雜性。創新研究領域包括開發非鴉片類藥物疼痛管理解決方案，最大限度地減少或消除便秘風險，以及利用數位健康工具有效監測和管理症狀。它還可以進行旨在闡明微生物組在 OIC 中的作用並發現新的治療標靶的研究。儘管存在這些挑戰，但隨著人口老化和慢性疼痛盛行率的增加，OIC 治療的全球市場預計將擴大。這一領域的從業者專注於開發以患者為中心的整體護理模式，以應對不斷變化的監管標準，促進與醫療保健提供者的合作，並整合尖端的治療方案，從而提高市場滲透率。

主要市場統計
基準年[2023] 6595萬美元
預測年份 [2024] 7010 萬美元
預測年份 [2030] 1.0378億美元
複合年成長率（%） 6.69%

市場動態：揭示快速發展的鴉片類藥物引起的便秘市場的關鍵市場洞察

鴉片類藥物引起的便秘市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 便秘老年人口增多
    • 腎臟疾病盛行率增加
    • 擴大多種治療方法的可用性
  • 市場限制因素
    • 核准流程嚴格，工作耗時
  • 市場機會
    • 擴大鴉片類藥物的使用
    • 零售藥局的供應量增加
  • 市場挑戰
    • 對鴉片類藥物耐受性和成癮的擔憂

波特的五力戰略工具駕馭鴉片類藥物引起的便秘市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解鴉片類藥物引起的便秘市場的外部影響

外部宏觀環境因素在塑造鴉片類藥物引起的便秘市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解鴉片類藥物引起的便秘市場的競爭格局

鴉片類藥物引起的便秘市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣供應商在鴉片類藥物引起的便秘市場的績效評估

FPNV 定位矩陣是評估鴉片類藥物引起的便秘市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了鴉片類藥物引起的便秘市場的成功之路

對鴉片類藥物引起的便秘市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 患有便秘併發症的老年人口不斷增加
      • 腎臟疾病增加
      • 各種治療方法的普及
    • 抑制因素
      • 核准流程嚴格、耗時
    • 機會
      • 鴉片類藥物的使用增加
      • 零售藥局的供應量增加
    • 任務
      • 對鴉片類藥物耐受性和成癮的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章活性成分鴉片類藥物引起的便秘市場

  • 膨脹性瀉藥、刺激性瀉藥
  • 多庫酯鈉
  • 軟化劑/潤滑劑 瀉藥
  • 魯比前列酮
  • 溴化甲基納曲酮
  • 納洛昔康
  • 滲透性瀉藥
  • 琴酒/胃腸動力促進劑

第 7 章 按藥物類別分類的鴉片類藥物引起的便秘市場

  • 局部作用氯離子通道活化劑 (LAACCA)
  • 非選擇性鴉片拮抗劑
  • 周邊限制性μ鴉片受體拮抗劑（PAMORA）
  • μ-鴉片拮抗劑

第8章 依給藥方式分類的鴉片類藥物所引起的便秘市場

  • 口服
  • 胃腸外的

第9章鴉片類藥物引起的便秘市場：依通路

  • 藥局
  • 醫院藥房
  • 獨立藥房

第10章美洲鴉片類藥物引起的便秘市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太鴉片類藥物引起的便秘市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲鴉片類藥物引起的便秘市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ironwood Pharmaceuticals, Inc.
  • Lantheus
  • Mylan by Viatris Inc.
  • Pfizer, Inc.
  • RedHill Biopharma Inc.
  • Salix Pharmaceuticals by Bausch Health Companies Inc.
  • Shionogo & Co. Ltd.
  • SLA Pharma AG
  • Synergy Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD5182A30

The Opioid Induced Constipation Market was valued at USD 65.95 million in 2023, expected to reach USD 70.10 million in 2024, and is projected to grow at a CAGR of 6.69%, to USD 103.78 million by 2030.

Opioid Induced Constipation (OIC) is a common side effect among patients using opioid analgesics for pain management, posing a significant area of interest for pharmaceutical companies and healthcare providers. The increasing prevalence of chronic pain and the subsequent rise in opioid consumption drive the necessity for effective OIC management solutions. Key applications include prescription medications, over-the-counter remedies, and non-pharmacological interventions aimed at alleviating constipation symptoms. The end-users span across hospitals, home care settings, and specialty clinics. Key growth influencers include the growing awareness surrounding opioid side effects, advancements in drug formulations, and increased healthcare spending. The latest opportunities lie in personalized medicine approaches, focusing on patient-specific solutions that consider genetic and lifestyle factors influencing constipation. Companies can capitalize on these opportunities by investing in patient education and developing comprehensive OIC management programs. However, market growth faces challenges such as stringent regulatory requirements for new drug approvals, the stigma associated with long-term opioid use, and the complexity of accurately diagnosing OIC versus other types of constipation. Innovation areas ripe for exploration include developing non-opioid pain management solutions that minimize or eliminate the risk of constipation, as well as leveraging digital health tools to monitor and manage symptoms effectively. Research can also be targeted towards understanding the microbiome's role in OIC, offering insights into novel therapeutic targets. Despite these challenges, the global market for OIC therapies is expected to grow as the aging population and incidence of chronic pain increase. Businesses within this niche can enhance market penetration by aligning with evolving regulatory standards, fostering collaborations with healthcare providers, and emphasizing the development of holistic and patient-centric care models that integrate cutting-edge treatment options.

KEY MARKET STATISTICS
Base Year [2023] USD 65.95 million
Estimated Year [2024] USD 70.10 million
Forecast Year [2030] USD 103.78 million
CAGR (%) 6.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Opioid Induced Constipation Market

The Opioid Induced Constipation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population with constipation complications
    • Growing prevalence of kidney disorders
    • Surging availability of diversified treatments
  • Market Restraints
    • Stringent approval process and time-consuming
  • Market Opportunities
    • Proliferating use of opioids
    • Rise in availability in retail pharmacies
  • Market Challenges
    • Concern regarding opioid tolerance and addiction

Porter's Five Forces: A Strategic Tool for Navigating the Opioid Induced Constipation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Opioid Induced Constipation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Opioid Induced Constipation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Opioid Induced Constipation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Opioid Induced Constipation Market

A detailed market share analysis in the Opioid Induced Constipation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Opioid Induced Constipation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Opioid Induced Constipation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Opioid Induced Constipation Market

A strategic analysis of the Opioid Induced Constipation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Opioid Induced Constipation Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ironwood Pharmaceuticals, Inc., Lantheus, Mylan by Viatris Inc., Pfizer, Inc., RedHill Biopharma Inc., Salix Pharmaceuticals by Bausch Health Companies Inc., Shionogo & Co. Ltd., SLA Pharma AG, Synergy Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Opioid Induced Constipation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Active Ingredients, market is studied across Bulk Cathartics, Stimulant Cathartics, Docusate Sodium, Emollient/Lubricant Cathartics, Lubiprostone, Methylnaltrexone Bromide, Naloxegol, Osmotic laxatives, and Prostaglandins/Prokinetic Drugs.
  • Based on Drug Class, market is studied across Locally Acting Chloride Channel Activator (LACCA), Non-Selective Opioid Antagonist, Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA), and μ-Opioid Antagonist.
  • Based on Mode of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Independent Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population with constipation complications
      • 5.1.1.2. Growing prevalence of kidney disorders
      • 5.1.1.3. Surging availability of diversified treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent approval process and time-consuming
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferating use of opioids
      • 5.1.3.2. Rise in availability in retail pharmacies
    • 5.1.4. Challenges
      • 5.1.4.1. Concern regarding opioid tolerance and addiction
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Opioid Induced Constipation Market, by Active Ingredients

  • 6.1. Introduction
  • 6.2. Bulk Cathartics, Stimulant Cathartics
  • 6.3. Docusate Sodium
  • 6.4. Emollient/Lubricant Cathartics
  • 6.5. Lubiprostone
  • 6.6. Methylnaltrexone Bromide
  • 6.7. Naloxegol
  • 6.8. Osmotic laxatives
  • 6.9. Prostaglandins/Prokinetic Drugs

7. Opioid Induced Constipation Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Locally Acting Chloride Channel Activator (LACCA)
  • 7.3. Non-Selective Opioid Antagonist
  • 7.4. Peripherally-Restricted μ-Opioid Receptor Antagonist (PAMORA)
  • 7.5. μ-Opioid Antagonist

8. Opioid Induced Constipation Market, by Mode of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Opioid Induced Constipation Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Store
  • 9.3. Hospital Pharmacies
  • 9.4. Independent Pharmacies

10. Americas Opioid Induced Constipation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Opioid Induced Constipation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Opioid Induced Constipation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Fresenius Kabi AG
  • 3. GlaxoSmithKline PLC
  • 4. Hikma Pharmaceuticals PLC
  • 5. Ironwood Pharmaceuticals, Inc.
  • 6. Lantheus
  • 7. Mylan by Viatris Inc.
  • 8. Pfizer, Inc.
  • 9. RedHill Biopharma Inc.
  • 10. Salix Pharmaceuticals by Bausch Health Companies Inc.
  • 11. Shionogo & Co. Ltd.
  • 12. SLA Pharma AG
  • 13. Synergy Pharmaceuticals Inc.
  • 14. Takeda Pharmaceutical Company Limited
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPIOID INDUCED CONSTIPATION MARKET RESEARCH PROCESS
  • FIGURE 2. OPIOID INDUCED CONSTIPATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPIOID INDUCED CONSTIPATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPIOID INDUCED CONSTIPATION MARKET DYNAMICS
  • TABLE 7. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY BULK CATHARTICS, STIMULANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DOCUSATE SODIUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY EMOLLIENT/LUBRICANT CATHARTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LUBIPROSTONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY METHYLNALTREXONE BROMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NALOXEGOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY OSMOTIC LAXATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PROSTAGLANDINS/PROKINETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY LOCALLY ACTING CHLORIDE CHANNEL ACTIVATOR (LACCA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY NON-SELECTIVE OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PERIPHERALLY-RESTRICTED M-OPIOID RECEPTOR ANTAGONIST (PAMORA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY M-OPIOID ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY ACTIVE INGREDIENTS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM OPIOID INDUCED CONSTIPATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. OPIOID INDUCED CONSTIPATION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. OPIOID INDUCED CONSTIPATION MARKET, FPNV POSITIONING MATRIX, 2023